Teneligliptin, a Dipeptidyl Peptidase-4 Inhibitor, Improves Early-Phase Insulin Secretion in Drug-Naïve Patients with Type 2 Diabetes

被引：7

作者：

Ito R. ^{[1
]}

Fukui T. ^{[1
]}

Hayashi T. ^{[1
]}

Osamura A. ^{[1
]}

Ohara M. ^{[1
]}

Hara N. ^{[1
]}

Higuchi A. ^{[1
]}

Yamamoto T. ^{[1
]}

Hirano T. ^{[1
]}

机构：

[1] Division of Diabetes, Metabolism, and Endocrinology, Department of Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo

来源：

Drugs in R&D | 2015年 / 15卷 / 3期

关键词：

Insulin Secretion; Glucagon; Oral Glucose Tolerance Test; Insulinogenic Index; Incretin Effect;

D O I：

10.1007/s40268-015-0096-6

中图分类号：

学科分类号：

摘要：

Introduction: It remains unknown whether dipeptidyl peptidase-4 (DPP-4) inhibitors improve early-phase insulin secretion in Japanese patients with type 2 diabetes (T2D), a disease characterized by impaired insulin secretion. We investigated the changes in insulin secretion before and after treatment with the DPP-4 inhibitor teneligliptin in patients with T2D with a low insulinogenic index (IGI) determined by the oral glucose tolerance test (OGTT). Methods: An open-label, prospective clinical study was conducted. Thirteen drug-naïve patients (mean age 55.5 ± 3.9 years) with T2D underwent OGTT before and after teneligliptin 20 mg/day monotherapy. Plasma levels of glucose (PG), insulin, and C-peptide were measured at 0, 30, 60, 90, and 120 min after glucose loading in the OGTT. Homeostasis model assessment (HOMA)-β, IGI, and the total or incremental area under the curve (AUC) for PG and insulin were measured. AUC120min for the secretory units of islets in transplantation (SUIT) index was also measured. Results: HbA1c significantly decreased from 8.3 ± 0.4 % at baseline to 6.3 ± 0.2 % after 12 weeks of teneligliptin treatment (p < 0.05). Incremental AUC120min PG also significantly decreased, and β-cell function assessed by IGI30min, AUC120min insulin, and the AUC120min SUIT index significantly increased (0.16 ± 0.05 vs. 0.28 ± 0.06, 2692 ± 333 µU·2h/mL vs. 3537 ± 361 µU·2h/mL, and 4261 ± 442 vs. 8290 ± 1147, respectively; all p < 0.05). HOMA-β was unchanged. The reduction in incremental AUC120min PG was significantly associated with the augmentation of IGI30min and the AUC120min SUIT index. No severe adverse events were observed. Conclusions: Twelve weeks of teneligliptin treatment improved IGI30min, AUC120min, and the SUIT index in drug-naïve Japanese patients with T2D. © 2015, The Author(s).

引用

页码：245 / 251

页数：6

共 22 条

[1]

Zimmet P., Alberti K.G., Shaw J., Global and societal implications of the diabetes epidemic, Nature., 414, pp. 782-787, (2001)

[2]

Chan J.C., Malik V., Jia W., Et al., Diabetes in Asia: epidemiology, risk factors, and pathophysiology, JAMA., 301, pp. 2129-2140, (2009)

[3]

Ahren B., Landin-Olsson M., Jansson P.A., Et al., Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes, J Clin Endocrinol Metab., 89, pp. 2078-2084, (2004)

[4]

Eto T., Inoue S., Kadowaki T., Effects of once-daily teneligliptin on 24-h blood glucose control and safety in Japanese patients with type 2 diabetes mellitus: a 4-week, randomized, double-blind, placebo-controlled trial, Diabetes Obes Metab., 14, pp. 1040-1046, (2012)

[5]

Rauch T., Graefe-Mody U., Deacon C.F., Et al., Linagliptin increases incretin levels, lowers glucagon, and improves glycemic control in type 2 diabetes mellitus, Diabetes Ther., 3, (2012)

[6]

Kadowaki T., Kondo K., Efficacy and safety of teneligliptin in combination with pioglitazone in Japanese patients with type 2 diabetes mellitus, J Diabetes Investig., 27, pp. 576-584, (2013)

[7]

He Y.L., Wang Y., Bullock J.M., Et al., Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT, J Clin Pharmacol., 47, pp. 633-641, (2007)

[8]

Lim S., An J.H., Shin H., Et al., Factors predicting therapeutic efficacy of combination treatment with sitagliptin and metformin in type 2 diabetic patients: the COSMETIC study, Clin Endocrinol., 77, pp. 215-223, (2012)

[9]

Yamada Y., Fukuda K., Fujimoto S., Et al., SUIT, secretory units of islets in transplantation: an index for therapeutic management of islet transplanted patients and its application to type 2 diabetes, Diabetes Res Clin Pract., 74, pp. 222-226, (2006)

[10]

Funakoshi S., Fujimoto S., Hamasaki A., Et al., Analysis of factors influencing pancreatic beta-cell function in Japanese patients with type 2 diabetes: association with body mass index and duration of diabetic exposure, Diabetes Res Clin Pract., 82, pp. 353-358, (2008)

← 1 2 3 →